Drugs / TCR1188-ABC cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07594067 | Jul 2026 → Jul 2042 expected | cholangiocarcinoma, colorectal cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma | University of Pennsylvania | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR1188-ABC cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07594067 ↗ |
| Modality | Cell therapy | “Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells” NCT07594067 ↗ |
| Route | Other | “as a Single infusion on Day 0” NCT07594067 ↗ |
| Target | KRAS | “Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells” NCT07594067 ↗ |